Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ferdous Al-Faruque

Senior Reporter

Washington, DC
Ferdous Al-Faruque, known as Danny, specializes in reporting on new medical device technologies such as mobile health, combination products, unique device identifiers, and issues surrounding interoperability and cyber security. He is also our resident podcast expert, and has brought listeners the voices of top FDA officials as well as industry leaders. Danny is a big sci-fi fan, especially Battlestar Galactica and Star Trek. Qapla'!
Advertisement
Set Alert for Articles By Ferdous Al-Faruque

Latest From Ferdous Al-Faruque

Abiomed Touts New Study Results, Potential To Revolutionize Heart-Attack Treatment

Promising new results from a pilot study of Abiomed’s Impella device to reduce damage after myocardial infarction sets the company up to start a pivotal study, which, if successful, could change how patients are treated immediately after an attack.

Clinical Trials Research & Development

AdvaMed Making Push For Device Tax Repeal In Lame Duck Session

The "lame duck" session of Congress before newly elected members take their seats in January may be the best shot available for the device industry to win permanent device tax repeal, lobby group AdvaMed says. The group is making a major effort to repeal the tax before the new Congress takes over.

Legislation Policy

Device Week, Nov. 9, 2018 – What The US Midterms Mean For Medtech

On this week's podcast, David Filmore and Ferdous Al-Faruque discuss the results of this week's midterm elections in the US and what it could mean for the medtech sector.

Device Week Elections

NEST Test Cases Could Support Company Submissions And Determine Future Of National Device Database

Recently announced US National Evaluation System for health Technology "test cases" will be evaluated for up to a year by the NEST Coordinating Center after which collaborating device-makers may be in a better position to use real-world evidence to support new pre-market device submissions. The test cases will be measured, in part, based on their ability to identify brand-specific devices in the NEST Network Collaborators’ real-world datasets.

Clinical Trials Health Technology Assessment

Gaps Remain In US FDA's Response Procedures For Cybersecurity Events, OIG Says

FDA's policies and procedures do not adequately address how to handle post-market device cybersecurity events and the agency had not adequately tested its ability to respond to emergencies arising from such events, US HHS' investigative arm says. But the top cybersecurity official at FDA's device center says OIG's report is "incomplete and inaccurate."

Cybersecurity Digital Health

Top FDA Officials Warn About Non-Vetted Pharmacogenetic Tests After Latest 23andMe Approval

A day after 23andMe gained US FDA go-ahead for a DTC genetic test service to inform patients about their ability to metabolize medications, the agency issued a safety communication, paired with a joint statement from device- and drug-center heads, warning consumers against trusting genetic tests that have not been vetted by FDA.

Approvals Safety
See All
Advertisement
UsernamePublicRestriction

Register